search
Back to results

Durability of Combination of Insulin and GLP-1 Receptor Agonist or SGLT-2 Inhibitors Versus Basal Bolus Insulin Regimen in Type 2 Diabetes (BEYOND) (BEYOND)

Primary Purpose

Type 2 Diabetes

Status
Completed
Phase
Phase 4
Locations
Italy
Study Type
Interventional
Intervention
IDegLira
IGlarLixi
Insulin/Canaglifozin
Insulin/Dapaglifozin
Insulin/Empaglifozin
Basal Bolus
Sponsored by
University of Campania "Luigi Vanvitelli"
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Type 2 Diabetes focused on measuring type 2 diabetes, GLP-1RA, SGLT-2i, basal insulin, basal bolus, glycemic control

Eligibility Criteria

35 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Poor glycemic control (HbA1c ≥7.5%)
  • Stable basal bolus insulin regimen for almost a year, eventually associated with metformin.

Exclusion Criteria:

  • Type 1 diabetes or secondary diabetes;
  • Previous treatment for the last three months with GLP-1RA or DPP-4 inhibitors;
  • Hypersensitivity towards active substances or other ingredients of the drugs used in the study
  • Participation in other trial with experimental drugs within 30 days
  • Diseases that represent contraindication to GLP-1RA use (pancreatitis, gallstones)
  • Pregnancy or planned pregnancy within the time of the study
  • Serum creatinine > 1,3 mg/dL in women and >1,4 mg/dL in men
  • eGFR < 30 mL/min
  • Previous cancer or antineoplastic therapy for five years before randomization
  • Current therapy with glucocorticoid (oral, topic or sistemic administration) or with antypsichotic drugs
  • Previous ketoacidosis
  • Any clinical, psychologic or psychiatric condition that is incompatible with the study according to the investigator

Sites / Locations

  • Unit of Endocrinology and Metabolic Diseases

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Active Comparator

Active Comparator

Active Comparator

Arm Label

FR insulin/GLP-1RA

Insulin/SGLT-2i

Basal Bolus

Arm Description

Patients in this arm will receive one of these fixed ratio combo of insulin and GLP-1RAs, according to the current clinical practice and the drugs' data sheet: IDegLira or IGlarLixi

Patients in this arm will receive the basal insulin used before the randomization and one of these SGLT-2i according to the current clinical practice and the drugs' data sheet: canagliflozin, dapagliflozin or empagliflozin.

Patients in this arm will receive a basal insulin (glargine, glargine-300 or degludec) at bed-time plus 3 injections of a short-acting insulin analogue (aspart, lispro or glulisine) before meals

Outcomes

Primary Outcome Measures

Hba1c change
HbA1c group difference at 6 months
Proportions of patients with significant HbA1c change
Proportions of patients undergoing a reduction equal or higher than 0.5% as compared with baseline levels during the follow up

Secondary Outcome Measures

Weight Change
BMI Change
Waist circumference change
Blood pressure change
Fasting glycemia change
Post-prandial glycemia change
C-peptide change
Change in total daily insulin dose
Change in lipide profile
Difference between groups in total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides
Change in eGFR
Diabetes treatment satisfaction
In order to measure satisfaction with diabetes treatment regimens, we used the self-reported Diabetes Treatment Satisfaction Questionnaire. This instrument aims to assess levels of satisfaction in subjects using different treatment strategies. The questionnaire consists of eight questions: six questions addresses general satisfaction with a score from 0 to 6 for each question (0 = worst), that has to be computed in a total score ranging from 0 (=worst) to 36 (=best); among the remaining two questions, which has to be computed separately as two subscales, one concerns the perception of hyperglycemic events and another the perception of hypoglycemic events, both with a score from 0 (none of the time) to 6 (most of the time).

Full Information

First Posted
December 6, 2019
Last Updated
October 20, 2020
Sponsor
University of Campania "Luigi Vanvitelli"
search

1. Study Identification

Unique Protocol Identification Number
NCT04196231
Brief Title
Durability of Combination of Insulin and GLP-1 Receptor Agonist or SGLT-2 Inhibitors Versus Basal Bolus Insulin Regimen in Type 2 Diabetes (BEYOND)
Acronym
BEYOND
Official Title
Durability of Combination of Insulin and GLP-1 Receptor Agonist or SGLT-2 Inhibitors Versus Basal Bolus Insulin Regimen in Type 2 Diabetes: a Randomized Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
October 2020
Overall Recruitment Status
Completed
Study Start Date
November 27, 2019 (Actual)
Primary Completion Date
September 30, 2020 (Actual)
Study Completion Date
October 20, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Campania "Luigi Vanvitelli"

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No

5. Study Description

Brief Summary
BEYOND represents an open-label, parallel, three-arm randomized controlled trial, aimed at evaluating the effects of combination therapy of fixed ratio basal insulin/GLP-1 receptor agonist (GLP-1RA) or basal insulin/SGLT-2 inhibitors (SGLT-2i) on the durability of the glycemic control, as compared with the basal bolus insulin regimen, in people with type 2 diabetes failing to achieve glycemic targets with injective therapy. The potential benefits for participants in the study include the possibility of improving the glyco-metabolic control with drugs that have been evaluated as safe and protective for the heart and the kidneys. The primary outcome of the study is the mean HbA1c change between groups at six months. Participants in the study will be followed for subsequent 18 months in order to evaluate the durability of glycemic control and the chenge of other secondary outcomes.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes
Keywords
type 2 diabetes, GLP-1RA, SGLT-2i, basal insulin, basal bolus, glycemic control

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
258 (Actual)

8. Arms, Groups, and Interventions

Arm Title
FR insulin/GLP-1RA
Arm Type
Active Comparator
Arm Description
Patients in this arm will receive one of these fixed ratio combo of insulin and GLP-1RAs, according to the current clinical practice and the drugs' data sheet: IDegLira or IGlarLixi
Arm Title
Insulin/SGLT-2i
Arm Type
Active Comparator
Arm Description
Patients in this arm will receive the basal insulin used before the randomization and one of these SGLT-2i according to the current clinical practice and the drugs' data sheet: canagliflozin, dapagliflozin or empagliflozin.
Arm Title
Basal Bolus
Arm Type
Active Comparator
Arm Description
Patients in this arm will receive a basal insulin (glargine, glargine-300 or degludec) at bed-time plus 3 injections of a short-acting insulin analogue (aspart, lispro or glulisine) before meals
Intervention Type
Drug
Intervention Name(s)
IDegLira
Intervention Description
IDegLira will be started at 16 dose steps (16 U insulin degludec plus 0.58 mg liraglutide, once daily). On the basis of prebreakfast self-monitored blood glucose measurements doses of IDegLira will be titrated individually twice per week to achieve a prebreakfast plasma glucose of 80-130 mg/dL by use of an algorithm (adding 2 dose steps for prebreakfast plasma glucose >130 mg/dL; no dose change for prebreakfast plasma glucose of 80-130 mg/dL; reducing 2 dose steps for prebreakfast plasma glucose < 80 mg/dL). The daily dose of IDegLira could be titrated to 50 dose steps (50 U insulin degludec plus 1.8 mg liraglutide).
Intervention Type
Drug
Intervention Name(s)
IGlarLixi
Intervention Description
IGlarLixi will be started at 10 dose steps (10 U insulin glargine plus 5 mcg lixisenatide, once daily). On the basis of prebreakfast self-monitored blood glucose measurements, doses of IGlarLixi will be titrated individually once per week to achieve a prebreakfast plasma glucose of 80-130 mg/dL by use of an algorithm (adding 2 dose steps for prebreakfast plasma glucose >130 mg/dL; no dose change for prebreakfast plasma glucose of 80-130 mg/dL; reducing 2 dose steps for prebreakfast plasma glucose < 80 mg/dL). The daily dose of IGlarLixi could be titrated to 60 dose steps (60 U insulin degludec plus 20 mcg lixisenatide).
Intervention Type
Drug
Intervention Name(s)
Insulin/Canaglifozin
Intervention Description
Patients in this arm will continue the basal insulin used before the randomization, with dosage titration on the basis of the following algorithm: adding 2 units for prebreakfast plasma glucose >130 mg/dL; no dose change for prebreakfast plasma glucose of 80-130 mg/dL; reducing 2 units for prebreakfast plasma glucose < 80 mg/dL. Moreover, they will be assigned to canaglifozin, according to the current clinical practice and the drugs' data sheet. Canagliflozin will be started at 100 mg daily per oral administration, and augmented to 300 mg/per day if required (HbA1c >7.5 after 12 weeks).
Intervention Type
Drug
Intervention Name(s)
Insulin/Dapaglifozin
Intervention Description
Patients in this arm will continue the basal insulin used before the randomization, with dosage titration on the basis of the following algorithm: adding 2 units for prebreakfast plasma glucose >130 mg/dL; no dose change for prebreakfast plasma glucose of 80-130 mg/dL; reducing 2 units for prebreakfast plasma glucose < 80 mg/dL. Moreover, they will be assigned to dapaglifozin, according to the current clinical practice and the drugs' data sheet. Dapagliflozin will be started at 10 mg daily per oral administration
Intervention Type
Drug
Intervention Name(s)
Insulin/Empaglifozin
Intervention Description
Patients in this arm will continue the basal insulin used before the randomization, with dosage titration on the basis of the following algorithm: adding 2 units for prebreakfast plasma glucose >130 mg/dL; no dose change for prebreakfast plasma glucose of 80-130 mg/dL; reducing 2 units for prebreakfast plasma glucose < 80 mg/dL. Moreover, they will be assigned to empaglifozin, according to the current clinical practice and the drugs' data sheet. Empagliflozin will be started at 10 mg daily per oral administration, and augmented to 25 mg/per day if required (HbA1c >7.5 after 12 weeks).
Intervention Type
Drug
Intervention Name(s)
Basal Bolus
Intervention Description
Patients in this arm will continue the basal insulin (glargine, degludec or glargine-300) used before the randomization. The insulin titration will be guided by the medical staff, according to the following algorithm: adding 2 units of basal insulin for prebreakfast plasma glucose >130 mg/dL; no dose change for prebreakfast plasma glucose of 80-130 mg/dL; reducing 2 units of basal insulin for prebreakfast plasma glucose < 80 mg/dL. The short acting insulin analogue (lispro, aspart or glulisine) will be started at the dosage of 4 units before meals (3 times per day) and will be titrated twice a week until achieving pre-prandial glucose values ranging from 80-130 mg/dL.
Primary Outcome Measure Information:
Title
Hba1c change
Description
HbA1c group difference at 6 months
Time Frame
6 months, 9 months, 12 months
Title
Proportions of patients with significant HbA1c change
Description
Proportions of patients undergoing a reduction equal or higher than 0.5% as compared with baseline levels during the follow up
Time Frame
Baseline, 3 months, 6 months, 9 months, 12 months, 18 months
Secondary Outcome Measure Information:
Title
Weight Change
Time Frame
Baseline, 6 months, 18 months
Title
BMI Change
Time Frame
Baseline, 6 months, 18 months
Title
Waist circumference change
Time Frame
Baseline, 6 months, 18 months
Title
Blood pressure change
Time Frame
Baseline, 6 months, 18 months
Title
Fasting glycemia change
Time Frame
Baseline, 6 months, 18 months
Title
Post-prandial glycemia change
Time Frame
Baseline, 6 months, 18 months
Title
C-peptide change
Time Frame
Baseline, 6 months, 18 months
Title
Change in total daily insulin dose
Time Frame
Baseline, 6 months, 18 months
Title
Change in lipide profile
Description
Difference between groups in total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides
Time Frame
Baseline, 6 months, 18 months
Title
Change in eGFR
Time Frame
Baseline, 6 months, 18 months
Title
Diabetes treatment satisfaction
Description
In order to measure satisfaction with diabetes treatment regimens, we used the self-reported Diabetes Treatment Satisfaction Questionnaire. This instrument aims to assess levels of satisfaction in subjects using different treatment strategies. The questionnaire consists of eight questions: six questions addresses general satisfaction with a score from 0 to 6 for each question (0 = worst), that has to be computed in a total score ranging from 0 (=worst) to 36 (=best); among the remaining two questions, which has to be computed separately as two subscales, one concerns the perception of hyperglycemic events and another the perception of hypoglycemic events, both with a score from 0 (none of the time) to 6 (most of the time).
Time Frame
Baseline, 6 months, 18 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
35 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Poor glycemic control (HbA1c ≥7.5%) Stable basal bolus insulin regimen for almost a year, eventually associated with metformin. Exclusion Criteria: Type 1 diabetes or secondary diabetes; Previous treatment for the last three months with GLP-1RA or DPP-4 inhibitors; Hypersensitivity towards active substances or other ingredients of the drugs used in the study Participation in other trial with experimental drugs within 30 days Diseases that represent contraindication to GLP-1RA use (pancreatitis, gallstones) Pregnancy or planned pregnancy within the time of the study Serum creatinine > 1,3 mg/dL in women and >1,4 mg/dL in men eGFR < 30 mL/min Previous cancer or antineoplastic therapy for five years before randomization Current therapy with glucocorticoid (oral, topic or sistemic administration) or with antypsichotic drugs Previous ketoacidosis Any clinical, psychologic or psychiatric condition that is incompatible with the study according to the investigator
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Katherine Esposito, MD, PhD
Organizational Affiliation
Unit of Diabetology University of Campania Luigi Vanvitelli
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Dario Giugliano, MD
Organizational Affiliation
Unit of Endocrinology and Metabolic Diseases University of Campania Luigi Vanvitelli
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Giuseppe Bellastella, MD, PhD
Organizational Affiliation
Unit of Endocrinology and Metabolic Diseases University of Campania Luigi Vanvitelli
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Maria Ida Maiorino, MD, PhD
Organizational Affiliation
Unit of Diabetology University of Campania Luigi Vanvitelli
Official's Role
Study Chair
Facility Information:
Facility Name
Unit of Endocrinology and Metabolic Diseases
City
Naples
ZIP/Postal Code
80138
Country
Italy

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
31715201
Citation
Giugliano D, Bellastella G, Maiorino MI, Esposito K. Beyond basal-bolus insulin regimen: Is it still the ultimate chance for therapy in diabetes? Diabetes Res Clin Pract. 2019 Nov;157:107922. doi: 10.1016/j.diabres.2019.107922. Epub 2019 Nov 9. No abstract available.
Results Reference
background
PubMed Identifier
33883195
Citation
Giugliano D, Longo M, Caruso P, Di Fraia R, Scappaticcio L, Gicchino M, Petrizzo M, Bellastella G, Maiorino MI, Esposito K. Feasibility of Simplification From a Basal-Bolus Insulin Regimen to a Fixed-Ratio Formulation of Basal Insulin Plus a GLP-1RA or to Basal Insulin Plus an SGLT2 Inhibitor: BEYOND, a Randomized, Pragmatic Trial. Diabetes Care. 2021 Jun;44(6):1353-1360. doi: 10.2337/dc20-2623. Epub 2021 Apr 21.
Results Reference
derived

Learn more about this trial

Durability of Combination of Insulin and GLP-1 Receptor Agonist or SGLT-2 Inhibitors Versus Basal Bolus Insulin Regimen in Type 2 Diabetes (BEYOND)

We'll reach out to this number within 24 hrs